ROS-responsive fluorinated polymer vesicle as well as preparation method and application thereof

CN118986889APending Publication Date: 2024-11-22THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411077743.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

[0003]目前临床上常用的治疗策略,如人工泪液、润滑凝胶/软膏和泪点塞,虽有助于缓解症状,但并不针对潜在的病因

Benefits of technology

[0037] (1) The fluorinated polymer vesicles have an internal hollow, vesicle-like structure, with an average particle size of 140 to 170 nm, a dispersion index of 0.05 to 0.09, and good particle size uniformity. As a carrier, they can uniformly load antibacterial drug;

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986889A_ABST
    Figure CN118986889A_ABST
Patent Text Reader

Abstract

The invention discloses an ROS-responsive fluorinated polymer vesicle and a preparation method and application thereof.The fluorinated polymer vesicle is of a vesicle-shaped structure with the hollow interior, and a fluorine-containing diblock polymer (poly (ethylene glycol) methyl ether methacrylate-trifluoroethyl methacrylate-phenylboronic acid ester) is dissolved in a good solvent firstly, and then the fluorine-containing diblock polymer (poly (ethylene glycol) methyl ether methacrylate-trifluoroethyl methacrylate-phenylboronic acid ester) is added into the good solvent; and then dissolving in a water phase and fully hydrating. The fluorinated polymer vesicle is good in in-vivo and in-vitro biocompatibility, has the capacity of responding to and removing ROS in cells, inhibits inflammation, can effectively and rapidly permeate tear films, keratoconjunctival membranes and cell membranes, has the capacity of rapidly releasing drugs and higher permeability, and can improve the drug utilization rate. The fluorinated polymer vesicle is used as a carrier and entraps MCC950, the fluorinated polymer vesicle and the MCC950 are synergistically and efficiently matched to respond and eliminate ROS (reactive oxygen species) and effectively reduce inflammatory response in NLRP3-Casepa-1-IL-1beta which is one of pathways causing xerophthalmia, and the fluorinated polymer vesicle is used for preparing the medicine for treating xerophthalmia, has excellent ocular surface bioavailability and greatly reduces the use frequency of eye medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a ROS-responsive fluorinated polymer vesicle, a preparation method and application thereof. Background Art

[0002] Dry eye disease (DED) is a multifactorial disease mainly caused by tear film hyperosmolarity. It currently affects about 30% of the world's population, with an incidence rate of up to 75% in adults over 40 years old, with women being the most affected. DED has become the most common ocular surface disease in the world and the second most common eye disease in ophthalmology clinics. It is mainly manifested by ocular surface dryness, foreign body sensation, photophobia, eye itching, painful burning sensation, blurred vision, etc., which increases the risk of ocular surface infection in patients (even developing into corneal ulcers). Severe dry eyes can even cause blindness in patients. It not only affects the quality of life of patients, but also creates an economic burden on society. At present, due to the high frequency and long-term reading of electronic screens such as mobile phones and computers, the incidence of dry eye disease has also increased, and it has shown a clear trend of younger age. In addition, DED has been shown to affect mental health. Population-based studies have shown that there is a relationship between depression, anxiety and DED. Therefore, the design and development of an efficient drug system for the treatment of dry eyes is of great significance in ophthalmology clinics.

[0003] Common treatment strategies currently used in clinical practice, such as artificial tears, lubricating gels / ointments, and punctal plugs, help relieve symptoms but do not target the underlying cause. Treatments aimed at reducing the inflammatory cycle, such as omega-3 fatty acid supplementation and cyclosporine drops, are no longer as effective as initially observed over time. Other anti-inflammatory treatments (such as corticosteroids) can lead to increased intraocular pressure and an increased risk of cataract formation when used for more than three months. Autologous serum eye drops that have been proven to have significant therapeutic effects lack availability and are expensive to produce, making them difficult to use in clinical practice. In many cases, one treatment regimen is insufficient to provide adequate relief, and a combination of multiple regimens is used, which increases the cost of living and the overall burden on patients.

[0004] Therefore, there is an urgent need to develop a safe and effective dry eye treatment to make up for the shortcomings of current clinical drug treatments. Summary of the invention

[0005] In order to solve the problems existing in the above-mentioned background technology, the purpose of the present invention is to provide a ROS-responsive fluorinated polymer vesicle, which has good in vitro and in vivo biocompatibility, has the ability to respond to and remove intracellular ROS, inhibits inflammation, can effectively and quickly penetrate the tear film, cornea and cell membrane, has the ability to quickly release drugs and stronger permeability, and can improve drug utilization. In addition, the present invention also provides a preparation method and application of the above-mentioned ROS-responsive fluorinated polymer vesicle, the fluorinated polymer vesicle is used as a carrier to encapsulate the water-soluble NLRP3 inhibitor MCC950, the two cooperate synergistically and efficiently, respond to and remove ROS, and can effectively downregulate the inflammatory response in NLRP3-Casepase-1-IL-1β, one of the pathways leading to the onset of dry eye DED, and the fluorinated polymer vesicle encapsulating MCC950 is used to prepare a drug for treating dry eye, which has excellent ocular surface bioavailability, will greatly reduce the frequency of use of ocular drugs, and effectively treat dry eye.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] In a first aspect of the present invention, there is provided a ROS-responsive fluorinated polymer vesicle, which is formed by first dissolving a fluorinated diblock polymer in a good solvent, then dissolving in an aqueous phase and fully hydrating;

[0008] The fluorinated diblock polymer is poly(ethylene glycol) methyl ether methacrylate-trifluoroethyl methacrylate-phenyl borate, and the fluorinated polymer vesicle is a vesicle-like structure with a hollow interior, an average particle size of 140-170 nm, and a dispersion index of 0.05-0.09.

[0009] Using the above technical solution:

[0010] The fluorinated polymer vesicle is hollow inside and has a vesicle-like structure. Its average particle size is 140 to 170 nm, its dispersion index is 0.05 to 0.09, and its particle size uniformity is good. As a carrier, it can evenly load antibacterial drugs. In the structure of the fluorinated polymer vesicle, a certain amount of fluorinated monomers are introduced to give the polymer vesicle the ability to quickly penetrate layers of physiological barriers such as mucin layers and cell membranes, optimizing the efficiency of drug delivery. The presence of phenylboronic acid ester fragments in the molecular chain can remove excess ROS in the ocular surface microenvironment and reduce the activation of NLRP3 inflammasomes. As an antibacterial drug nanocarrier, the fluorinated polymer vesicle can improve its ability to penetrate layers of anatomical physiological barriers, increase drug permeability and utilization, and the hydrophobic groups in the PTBA fragments in the fluorinated polymer vesicle can be oxidized into hydrophilic groups, which can increase the pores of the polymer vesicle F-PVs and help accelerate the release of drugs loaded in the inner cavity to the outside world.

[0011] Fluorinated polymer vesicles have good in vitro and in vivo biocompatibility, the ability to respond to and remove ROS, rapid drug release and stronger permeability. The treatment of SCOP-DED mice further proved that it can effectively treat dry eyes, and compared with non-fluorinated polymer vesicles, fluorinated vesicles have better therapeutic effects. This result shows that drug-loaded fluorinated polymer vesicles have great potential in the synergistic treatment of dry eye.

[0012] Preferably, the good solvent is DMF, and the usage ratio of the fluorinated diblock polymer to the good solvent is (9-11) mg:1 mL.

[0013] Preferably, the fluorinated diblock polymer is dissolved in a good solvent to form a solution A, and the volume ratio of the solution A to the aqueous phase is 1:(1.8-2.2).

[0014] The second aspect of the present invention provides a method for preparing the above-mentioned ROS-responsive fluorinated polymer vesicles, comprising the following steps:

[0015] S1. Synthesis of macromolecular chain transfer agent:

[0016] Using DMF as solvent, chain transfer agent CTA, AIBN as free radical initiator, PEGMA and TFEMA through reversible addition-fragmentation chain transfer polymerization to prepare the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA;

[0017] S2. Synthesis of phenylboronic acid ester:

[0018] 4-(Hydroxymethyl)phenylboronic acid pinacol ester was dissolved in excess anhydrous DCM, excess TEA was added, and after cooling, acryloyl chloride was added thereto to obtain phenylboronic acid ester through reaction;

[0019] S3. Synthesis of fluorinated diblock polymers:

[0020] The fluorinated diblock polymer was prepared by reversible addition-fragmentation chain transfer polymerization of phenyl borate with photoinitiator LAP as free radical initiator and macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA as chain transfer agent.

[0021] S4. Synthesis of fluorinated polymer vesicles:

[0022] The fluorinated diblock polymer is first dissolved in a good solvent, and under stirring conditions, the aqueous phase is slowly added to the solution and fully hydrated, and the stirring reaction is continued for a period of time. The obtained fluorinated polymer vesicle dispersion is transferred to a dialysis bag and dialyzed in deionized water. The deionized water is replaced regularly to remove the residual DMF to obtain fluorinated polymer vesicles.

[0023] Preferably, in step S1, the chain transfer agents CTA, AIBN, PEGMA and TFEMA are in a molar ratio of 1:(0.18-0.22):(8-10):(2.7-3.3).

[0024] More preferably, in step S1, the chain transfer agents CTA, AIBN, PEGMA and TFEMA have a molar ratio of 1: (0.19-0.21): (8.6-9.4): (2.8-3.2).

[0025] Preferably, in step S2, the molar ratio of 4-(hydroxymethyl)phenylboronic acid pinacol ester to acryloyl chloride is (9-11):1.

[0026] More preferably, in step S2, the molar ratio of 4-(hydroxymethyl)phenylboronic acid pinacol ester to acryloyl chloride is (9.7-10.4):1.

[0027] Preferably, in step S3, the molar ratio of the photoinitiator LAP, the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA and the phenyl borate is 1:(1.8-2.2):(89.9-109.9).

[0028] More preferably, in step S3, the molar ratio of the photoinitiator LAP, the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA, and the phenyl borate is 1:(1.9-2.1):(96-102).

[0029] Preferably, in step S4, the good solvent is DMF, the usage ratio of the fluorinated diblock polymer to the good solvent is (9-11) mg:1 mL, the fluorinated diblock polymer is dissolved in the good solvent to form solution A, and the volume ratio of solution A to deionized water in the aqueous phase is 1:(1.8-2.2).

[0030] More preferably, in step S4, the good solvent is DMF, the usage ratio of the fluorinated diblock polymer to the good solvent is (9.6-10.5) mg:1 mL, the fluorinated diblock polymer is dissolved in the good solvent to form solution A, and the volume ratio of solution A to deionized water in the aqueous phase is 1:(1.8-2.2).

[0031] The third aspect of the present invention provides a pharmaceutical composition, using the above-mentioned fluorinated polymer vesicles as a carrier to in situ encapsulate MCC950.

[0032] The specific preparation process is as follows:

[0033] In step S4, the fluorinated diblock polymer is first dissolved in a good solvent, and then dissolved in 1 mmol MCC950 sodium salt, and fully hydrated to obtain drug-loaded fluorinated polymer vesicles loaded with MCC950.

[0034] The fourth aspect of the present invention provides a use of the above-mentioned pharmaceutical composition, wherein the pharmaceutical composition is used to prepare a pharmaceutical preparation for treating dry eye. The pharmaceutical preparation is used for topical administration to the eye, and specifically, the pharmaceutical preparation is eye drops.

[0035] The fluorinated polymer vesicles are used as carriers to encapsulate the water-soluble NLRP3 inhibitor MCC950. The ability of the fluorinated polymer vesicles to quickly penetrate layers of physiological barriers such as mucin layers and cell membranes optimizes the efficiency of drug delivery. The phenylboronic acid fragment in the molecular structure can remove excess ROS in the ocular surface microenvironment, reduce the activation of NLRP3 inflammasomes, improve the bioavailability of MCC950, significantly reduce the frequency of use of ocular drugs, avoid frequent administration, and further enhance the anti-inflammatory effect of MCC950, thereby achieving synergistic and efficient dry eye treatment.

[0036] Compared with the prior art, the present invention has the following beneficial effects:

[0037] (1) The fluorinated polymer vesicles are hollow and vesicle-like in structure, with an average particle size of 140 to 170 nm, a dispersion index of 0.05 to 0.09, and good particle size uniformity. As a carrier, the antibacterial drug can be uniformly loaded;

[0038] (2) Introducing a certain amount of fluorinated monomers into the structure of fluorinated polymer vesicles can give the polymer vesicles the ability to quickly penetrate layers of physiological barriers such as mucin layers and cell membranes, thereby optimizing the efficiency of drug delivery. The presence of phenylboronic acid fragments in the molecular chain can remove excess ROS in the ocular surface microenvironment and reduce the activation of NLRP3 inflammasomes. As nanocarriers of antimicrobial drugs, the fluorinated polymer vesicles can improve their ability to penetrate layers of anatomical and physiological barriers, increase drug permeability and utilization, and the hydrophobic groups in the PTBA fragments in the fluorinated polymer vesicles can be oxidized into hydrophilic groups, which can increase the pores of the polymer vesicles F-PVs and help accelerate the release of drugs loaded in the inner cavity to the outside world;

[0039] (3) Fluorinated polymer vesicles have good in vitro and in vivo biocompatibility, the ability to respond to and remove ROS, rapid drug release and stronger permeability. The treatment of SCOP-DED mice further proved that they can effectively treat dry eyes, and compared with non-fluorinated polymer vesicles, fluorinated vesicles have better therapeutic effects;

[0040] (4) Fluorinated polymer vesicles are used as carriers to encapsulate the water-soluble NLRP3 inhibitor MCC950. The ability of fluorinated polymer vesicles to quickly penetrate physiological barriers such as mucin layers and cell membranes optimizes the efficiency of drug delivery. The phenylboronic acid fragment in the molecular structure can remove excess ROS in the ocular surface microenvironment, reduce the activation of NLRP3 inflammasomes, improve the bioavailability of MCC950, significantly reduce the frequency of ocular drug use, avoid frequent administration, and further enhance the anti-inflammatory effect of MCC950, thereby achieving synergistic and efficient dry eye treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0042] Figure 1 The synthetic route of P(PEGMA9-co-TFEMA3)-CTA is shown;

[0043] Figure 2 The synthetic route of phenylboronic acid ester PTBA (i: TEA, DCM, overnight);

[0044] Figure 3 The synthetic route of the fluorinated diblock polymer P(PEGMA9-co-TFEMA3)-b-PPTBA50 is shown;

[0045] Figure 4 The synthetic route of PPEGMA9-CTA is shown in Figure 2.

[0046] Figure 5 The synthetic route of PPEGMA9-b-PPTBA50 is shown;

[0047] Figure 6 Schematic diagram of corneal penetration diffusion experiment;

[0048] Figure 7 H NMR spectra (A) PPEGMA9-CTA (B) P(PEGMA9-co-TFEMA3)-CTA;

[0049] Figure 8 H NMR spectra (A) P(PEGMA9-co-TFEMA3)-b-PPTBA50 (B) PPEGMA9-b-PPTBA50;

[0050] Fig. 9 (A) Particle size distribution diagram of polymer vesicles F-PVs and F-PVs@M, (B) Particle size distribution diagram of polymer vesicles PVs and PVs@M, (C-D) Particle size distribution diagram of polymer vesicles F-PVs@FITC and PVs@FITC;

[0051] Fig.10Vesicle morphology images taken by TEM (left) F-PVs (right) F-PVs@M;

[0052] Fig.11 Vesicle morphology images taken by TEM (left) PVs (right) PVs@M;

[0053] Fig.12 This is the EDS-Mapping analysis diagram of F-PVs (blue is fluorine element, and the blue background is noise);

[0054] Fig.13 This is the EDS-Mapping analysis diagram of PVs (blue is fluorine element, and the background blue is noise);

[0055] Fig.14 In vitro cumulative release curves of FS from F-PVs@FS in the presence of different low concentrations of H2O2;

[0056] Fig.15 CCK-8 quantitative analysis of cell viability after co-incubation of polymer vesicles and HECEs (A) F-PVs (B) F-PVs@M (C) PVs (D) PVs@M;

[0057] Fig.16 For qualitative analysis by live / dead staining: Cell fluorescence images after co-incubation of polymersomes with HCECs (A) PVs@M (B) F-PVs@M;

[0058] Fig.17 These are images of mouse eyeballs taken using slit lamp diffuse light and cobalt blue light dotted with sodium fluorescein before and after one week of drug administration;

[0059] Fig.18 This is the H&E staining picture of the paraffin section of the mouse eyeball after continuous administration for one week;

[0060] Fig.19 The changes of intraocular pressure and body weight of mice after continuous drug administration for one week: (A) intraocular pressure (B) body weight;

[0061] Fig. 20 Cell uptake images taken by confocal microscopy after 40 μg / mL fluorescent polymer vesicles were co-incubated with HCECS for 0.5, 2, 4, and 6 hours; blue: DAPI, green: fluorescent polymer vesicles, objective lens magnification: 63×; (A) PVs@FITC (B) F-PVs@FITC;

[0062] Fig.21 is the cumulative permeation percentage of polymersomes penetrating the rabbit cornea;

[0063] Fig. 22Corneal tissue sections photographed with a confocal microscope after 100 μg / mL of polymer vesicles were continuously instilled into the eye for 10 times. Green: polymer vesicles, blue: DAPI, fluorescence objective magnification: 10×;

[0064] Fig.23 After continuous eye drops of 100 μg / mL polymer vesicles for 10 times, conjunctival tissue sections were photographed using a confocal microscope. Green: polymer vesicles, blue: DAPI, objective lens magnification: 10×;

[0065] Fig.24 For F-PVs in 200 μM HO 2 O 2 Responsive decomposition in ;

[0066] Fig.25 This is a representative effect diagram of fluorinated polymer vesicles clearing intracellular reactive oxygen species (green represents reactive oxygen species);

[0067] Fig.26 This is a representative image of the effect of polymer vesicles in treating dry eyes, taken under cobalt blue light of a slit lamp;

[0068] Fig. 27 To evaluate the efficacy of polymer vesicles in treating dry eye, fluorescein sodium score;

[0069] Fig.28 To evaluate the efficacy of polymer vesicles in treating dry eyes, tear secretion content;

[0070] Fig.29 Evaluation of the efficacy of polymer vesicles in treating dry eye: (left) intraocular pressure (right) body weight;

[0071] Fig.30 To evaluate the efficacy of polymer vesicles in treating dry eye, the number of conjunctival goblet cells was counted;

[0072] Fig.31 To evaluate the efficacy of polymer vesicles in treating dry eye, H&E staining of the whole body and conjunctiva, cornea, and retina was performed;

[0073] Fig.32 ELISA was used to analyze the inhibitory effect of polymersomes on the expression of IL-6, IL-1β, and TNF-α;

[0074] Fig.33 Immunofluorescence staining of mouse corneal tissue;

[0075] Fig.34 Immunofluorescence staining of mouse conjunctival tissue. DETAILED DESCRIPTION

[0076] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0077] The present invention is further described below by way of examples. Unless otherwise specified, the various reagents and raw materials used in the present invention are all commercially available products or products that can be prepared by known methods.

[0078] Example 1

[0079] Preparation of fluorinated polymersomes

[0080] S1. Synthesis of macromolecular chain transfer agent:

[0081] First, CTA (0.3505 g, 1.255 mmoL), PEGMA (4.0624 g, 11.284 mmoL), TFEMA (0.6326 g, 3.763 mmoL) and AIBN (41 mg, 0.25 mmoL) were added to the reaction bottle in sequence. DMF was used as the solvent. The solution was placed in a low temperature environment and purged with nitrogen for 30 minutes. The reaction bottle was placed in an oil bath at 70°C, and the speed was set to 290 rpm. After polymerization for 32.3 hours, the solution in the reaction bottle was exposed to air to terminate the polymerization. The polymer after the reaction was loaded into a dialysis bag with a molecular weight cutoff of 1000 Da, dialyzed in water for 48 hours, and then dried using a vacuum freeze dryer. After 96 hours, the final product was obtained and named P(PEGMA9-co-TFEMA3)-CTA. The synthesis route is as follows Figure 1 shown.

[0082] S2. Synthesis of phenylboronic acid ester PTBA:

[0083] 13.16g (56.2mmoL) of 4-(hydroxymethyl)phenylboronic acid pinacol ester was placed in a round-bottom flask, dissolved with 70mL (excess) of anhydrous DCM, 9.4mL (excess) of TEA was added, cooled to 0°C, and 509.6g (5.63mol) of acryloyl chloride was gradually added within 1h, the dripping rate was controlled, one drop was made every 1-2s, the rotation speed was set to 600rpm, and after standing overnight, filtration and extraction were performed. First, an eluent mixed with petroleum ether and ethyl acetate was used for elution. After thin layer chromatography confirmed that the reaction was complete, filtration was started: ethyl acetate was used for continuous dilution, and a small amount of dichloromethane was added after repeated filtration for 5 times, and then the solution was diluted again and rotary evaporated, and the temperature was set at 30°C; the liquid after rotary evaporation was transferred to a separatory funnel, shaken and allowed to stand for stratification, and the aqueous layer was removed and the reactant was dried with anhydrous magnesium sulfate and then filtered and rotary evaporated again, and finally 3.826g of product PTBA was obtained. The synthetic route is as follows Figure 2 shown.

[0084] S3. Synthesis of fluorinated diblock polymers:

[0085] Use 2.3mL of methanol to dissolve the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA (74.5mg, 0.0185mmoL), PTBA (0.2649g, 0.9192mmoL) and LAP (2.7mg, 0.0092mmoL), then mix and add to a 5mL crimp bottle, and ultrasonicate for 3min to mix the reactants evenly. After blowing the solution with nitrogen in an ice bath for 20min, keep the ice bath environment, place it under a 365nm UV lamp for reaction, set the speed to 300rpm, let it react fully, terminate the polymerization after 9h, take 50μL samples before and after the reaction for passing 1 The H NMR spectrum verified whether the synthesis was successful. The next day, the product was centrifuged four times at 4°C and 10,000 rpm. The final product was placed in a vacuum condensation dryer and dried for 48 hours. The final product was named P(PEGMA 9 -co-TFEMA 3 )-b-PPTBA50, the synthetic route is as follows Figure 3 shown.

[0086] S4. Synthesis of fluorinated polymer vesicles:

[0087] Dissolve 10.7 mg P(PEGMA) in 1.07 mL DMF. 9 -co-TFEMA 3)-b-PPTBA50, take 520 μL of the above solution and place it in a 5 mL cillin bottle, set the speed to 800 rpm, and slowly add 1.04 mL of deionized water using a micro syringe. In order to completely assemble the polymer, continue stirring for 2 hours, then transfer the vesicle dispersion to a dialysis bag with a molecular weight cutoff of 2000 Da, and dialyze in deionized water for 12 hours, changing the water every 30 minutes to remove the residual DMF, and obtain empty fluorinated polymer vesicles, named F-PVs.

[0088] Example 2

[0089] Preparation of drug-loaded MCC950 polymersomes:

[0090] Dissolve 10.7 mg P(PEGMA) in 1.07 mL DMF. 9 -co-TFEMA 3 )-b-PPTBA50, take 500 μL of the above solution and place it in a cillin bottle, set the speed to 800 rpm, and slowly add 1 mL of 1 mmol LMCC950 sodium salt using a micro syringe. In order to completely assemble the polymer, continue stirring for 2 hours, then transfer the vesicle dispersion to a dialysis bag with a molecular weight cutoff of 2000 Da, and dialyze in deionized water for 12 hours, changing the water every 30 minutes to remove the residual DMF, and obtain drug-loaded fluorinated polymer vesicles named F-PVs@M.

[0091] Example 3

[0092] Preparation of fluorescein sodium-fluoride polymersomes:

[0093] Fluorinated polymer vesicles loaded with hydrophilic fluorescein, sodium fluorescein FS, were prepared by solvent replacement method.

[0094] The specific experimental steps are as follows: prepare 5mg / mL fluorescein sodium solution, use 2mL DMF to dissolve 20mg P(PEGMA9-co-TFEMA3)-b-PPTBA50 diblock polymer, set the speed to 800rpm, use a micro syringe to slowly add 4mL 5mg / mL FS aqueous solution, and continue stirring for 2h to allow the polymer to be fully assembled. Then transfer the FS-vesicle dispersion to a dialysis bag with a molecular weight cutoff of 2000Da and dialyze in deionized water for 6h, replace the dialysate every hour to remove residual DMF and free FS, and the resulting product is named F-PVs@FS.

[0095] Example 4

[0096] Preparation of FITC-fluorinated polymersomes:

[0097] Fluorinated polymer vesicles loaded with hydrophobic fluorescein were prepared by solvent replacement method. FITC was dissolved in DMF to prepare a 5 mg / mL fluorescein isothiocyanate (FITC) solution. Take 0.5 mL of 10 mg / mL F-PVs / DMF solution, mix with 0.5 mL FITC solution and vortex for 10 minutes. Use a microsyringe to slowly add 2 mL of deionized water, stir overnight and dialyze. Use a 1000 Da dialysis bag to dialyze for 4 hours in the dark to remove free FITC and DMF, change the water 6 times, and obtain F-PVs@FITC, which is stored in the dark.

[0098] Example 5

[0099] Preparation of fluorine-free polymer vesicles

[0100] S1. Synthesis of macromolecular chain transfer agent:

[0101] The method is the same as step S1 in Example 1, except that the monomer TFEMA is removed, and the proportions and conditions of the other monomers are not changed. The specific experimental steps are as follows: CTA (0.1996 g, 0.7144 mmoL), PEGMA (2.3066 g, 6.4072 mmoL) and AIBN (57.6 mg, 0.3512 mmoL) are added to the reaction bottle, and then the same as above, the synthesis route is as follows Figure 4 As shown, named PPEGMA 9 -CTA.

[0102] S2. Synthesis of fluorine-free diblock polymers:

[0103] The method is basically the same as step S3 in Example 1, wherein the macromolecular chain transfer agent P(PEGMA 9 -co-TFEMA 3 )-CTA replaced by PEGMA 9 -CTA, the molar ratio of each monomer and other conditions remain unchanged, and the fluorine-free diblock polymer is obtained, which is named PPEGMA 9 -b-PPTBA50, the synthetic route is as follows Figure 5 shown.

[0104] S3. Synthesis of Fluorine-free Polymer Vesicles

[0105] The same solvent replacement method was used, and the specific experimental steps were the same as step S4 in Example 1. The fluorinated diblock polymer P(PEGMA 9 -co-TFEMA 3 )-b-PPTBA was replaced by fluorine-free diblock polymer PPEGMA 9 -b-PPTBA50, the obtained fluorine-free polymer vesicles were named PVs.

[0106] Example 6

[0107] Preparation of Fluorine-free Polymer Vesicles Loaded with MCC950:

[0108] The preparation method is the same as that in Example 2. The fluorinated diblock polymer P(PEGMA 9 -co-TFEMA 3 )-b-PPTBA was replaced by fluorine-free diblock polymer PPEGMA 9 -b-PPTBA50, the fluorine-free polymer vesicles loaded with MCC950 were prepared and named PVs@M.

[0109] Example 7

[0110] Preparation of fluorescein sodium-fluoride-free polymer vesicles:

[0111] Fluorine-free polymer vesicles loaded with hydrophilic fluorescein, sodium fluorescein FS, were prepared by solvent replacement method.

[0112] The specific experimental steps are as follows: prepare 5 mg / mL sodium fluorescein solution, use 3 mL DMF to mix 30 mg of fluorine-free diblock polymer PPEGMA 9 -b-PPTBA50 was dissolved, the speed was set to 800 rpm, 6 mL of 1.5 mg / mL FS aqueous solution was slowly added using a microsyringe, and stirring was continued for 2 h to facilitate complete assembly. The FS-vesicle dispersion was then transferred to a dialysis bag with a molecular weight cutoff of 2000 Da and dialyzed in deionized water for 6 h, with the dialysate replaced every hour to remove residual DMF and free FS, to obtain sodium fluorescein-fluorine-free polymer vesicles, named PVs@FS.

[0113] A fluorescence full-wavelength microplate reader was used to measure the fluorescence intensity of F-PVs@FS at an excitation wavelength of 495 nm and an emission wavelength of 515 nm, and then compared with the standard concentration curve of FS to calculate the loading amount of FS in the vesicles to simulate the encapsulation rate of PVs@M and store it away from light.

[0114] Example 8

[0115] Preparation of FITC-fluorine-free polymersomes:

[0116] Fluorine-free polymer vesicles loaded with hydrophobic fluorescein were prepared by solvent replacement method.

[0117] The specific experimental steps are as follows: Take 20 mg of the fluorine-free diblock polymer PPEGMA9-b-PPTBA50 and dissolve it in 2 mL of DMF, mix it with 1.2 mL of 1 mg / mL FITC solution and vortex it for 10 minutes. Use a microsyringe to slowly add 4.8 mL of deionized water, stir it overnight and then dialyze it. Use a 1000 Da dialysis bag to dialyze it for 4 hours in the dark to remove free FITC and DMF, change the water 6 times, and obtain FITC-fluorine-free polymer vesicles, named PVs@FITC, which are stored in the dark.

[0118] 1. Characterization of polymersomes

[0119] 1.1 H NMR

[0120] PTBA, P(PEGMA) 9 -co-TFEMA 3 )-CTA、PEGMA 9 -CTA, P(PEGMA 9 -co-TFEMA 3 )-b-PPTBA50, PPEGMA 9 -b-PPTBA50 was successfully synthesized.

[0121] 1.2 Dynamic light scattering

[0122] Dynamic light scattering, also known as photon correlation spectroscopy or quasi-elastic light scattering, is a physical characterization method used to measure the particle size distribution in a solution or suspension. The particle size analyzer was used to measure the concentrations of the prepared vesicles: F-PVs@M, F-PVs, F-PVs@FS, F-PVs@FITC, PVs@M, PVs, PVs@FS, and PVs@FITC were diluted to 0.2% with deionized water.

[0123] 1.3 Transmission electron microscopy

[0124] The sample preparation method is as follows: 10 μL of 0.2% concentration of F-PVs@M, F-PVs, PVs@M, PVs was dropped on a copper grid, left to dry naturally, and then placed in a 37°C incubator overnight. The surface morphology of the nanoparticles and the elemental distribution maps (EDS-Mapping) of F-PVs and PVs were observed at a voltage of 110 kV.

[0125] 1.4 Packing rate

[0126] Since the characteristic peak of the ultraviolet light of polymer vesicles overlaps with the characteristic peak of drug MCC950, fluorescein sodium (FS) was used as a simulant to measure the drug encapsulation rate. FS is a common ophthalmic dye. Since its water solubility and molecular weight are similar to those of MCC950, the fluorescence intensity of FS can also be quickly and conveniently measured using a fluorescence microplate reader.

[0127] The fluorescence intensity of F-PVs@FS and PVs@FS at an excitation wavelength of 495 nm and an emission wavelength of 515 nm was measured using a fluorescence full-wavelength microplate reader, and then compared with the standard concentration curve of FS to calculate the loading amount of FS in the vesicles, and thus the loading amount of the drug in the vesicles. The drug loading efficiency (DLE) and drug loading content (DLC) were calculated according to the equation:

[0128] DLE (%) = mass of drug in vesicles / drug input amount × 100%;

[0129] DLC (%) = the mass of the drug in the vesicles / the amount of polymer added × 100%.

[0130] 1.5 In vitro release

[0131] According to the design of this study, the block PTBA in the polymer vesicles can respond to low concentrations of H 2 O 2 , thereby accelerating the release of the encapsulated drug, here we use sodium fluorescein (FS) as a model molecule to explore the in vitro release behavior. After measuring the fluorescence intensity of FS, its concentration is calculated through the standard curve of FS, and finally the cumulative release rate of FS is calculated. Therefore, FS is selected as a model molecule to study the in vitro release behavior.

[0132] Briefly, the F-PVs@FS was first dialyzed for 3 h to remove free FS and DMF. Then, three 250 mL beakers were prepared and 200 mL of dialysis medium was added into them, including PBS buffer, 10 mM H 2 O 2 , 100 mM H 2 O 2 . 1mL FS@PPM was added to a dialysis bag with a molecular weight cutoff of 2000Da and 1mL of the corresponding dialysis medium was added thereto, then placed in the corresponding beaker and subjected to FS simulated release at a stirring speed of 300rpm. 200μL of dialysate was extracted from the dialysis bag at different time points, and its fluorescence intensity was measured with a fluorescence microplate reader to monitor the in vitro release behavior.

[0133] 2. Study on the biocompatibility of polymer vesicles

[0134] 2.1 In vitro biocompatibility

[0135] The cells used in this application are human 12-SV40 corneal epithelial cell line (CRL-11135, HCE-2) purchased from ATCC, USA, passage 20-30, hereinafter referred to as HCEC. The cells were cultured in a culture medium prepared by DMEM / F12 (1:1) cell culture medium: fetal bovine serum: penicillin-streptomycin = 90:9:1. The cells were cultured at 37°C and CO 2 The concentration was 5% and the humidity was 90% in an incubator. The culture medium, PBS, Trypsin-EDTA and other reagents used in the cell experiment were preheated in a 37°C water bath in advance.

[0136] 1. Cell recovery: Take out the HCEC cell cryopreservation tube stored in liquid nitrogen, immediately put it into a water bath preheated to 37°C, and gently shake it to make it evenly heated until it is completely melted, then transfer the cell cryopreservation solution to a sterile centrifuge tube and add 1mL of cell culture medium, blow it to mix it evenly, and then put it into a centrifuge, centrifuge it at 1000rpm for 3min. After aspirating the supernatant with a pipette, slowly add 1mL of culture medium, gently blow it 10-20 times to resuspend the cells, and then transfer 200μL of the cell resuspension to a T25 culture flask with 4mL of culture medium added in advance, shake it gently in an 8-shaped shape, and evenly spread the cells before placing it in a constant temperature cell culture incubator. Observe the cell state and cell density after 24h, and selectively replace the new culture medium.

[0137] 2. Cell medium replacement: 24 hours after cell recovery or subculture, observe the density and morphology of cell growth under a microscope. The specific experimental operation method is as follows: use a pipette to absorb all the old culture medium, slowly add 2mL PBS into the culture bottle, shake the culture bottle in an 8-shaped pattern to wash for 1 minute, discard the PBS, and add 4mL of new complete culture medium.

[0138] 3. Cell passaging: When the cells recover or about 48 hours after the last passaging, observe the cell morphology and density under a microscope. If the density has reached more than 80%, it should be passaged in time. The specific experimental operation method is as follows: use a pipette to absorb all the old culture medium, slowly add 2mL PBS to the culture bottle, shake the culture bottle in an 8-shaped pattern with a gentle hand to wash for 1 minute, then discard the PBS, add 2mL 0.25% Trypsin-EDTA, observe the cell morphology under a microscope, and place it in a 37℃ cell constant temperature incubator for digestion for 3 minutes. After taking it out, observe the cell morphology under a microscope to see if the edge has become rounded and has been free in the culture bottle, and quickly add an equal amount of culture medium to terminate the digestion. Transfer to a 15mL centrifuge tube and centrifuge at 1000rpm for 3 minutes. After the supernatant is aspirated by a pipette, 1 mL of culture medium is slowly added, and the cells are gently blown 10-20 times to resuspend them. Then 200 μL of the cell suspension is transferred to a T25 culture flask that has been pre-added with 4 mL of culture medium, and the flask is gently shaken in an 8-shaped pattern. The cells can be evenly spread before being placed in a constant temperature cell culture incubator. After 24 hours, the cell status and cell density are observed, and new culture medium is selectively replaced.

[0139] 4. Cell counting: Take 15 μL of the resuspended cell suspension and mix it with 15 μL of 0.4% trypan blue staining solution. Gently pipette 10-20 times to mix it evenly. Pipette 20 μL of the mixture into the cell counting plate and use the automatic cell fluorescence analyzer to read the cell survival rate, aggregation rate and cell density.

[0140] 5. Cell seeding plate: Choose the appropriate well plate size and cell seeding density according to the specific experiment, calculate the number of cells and final volume required for the experiment, take out the calculated volume of cell resuspension, add complete culture medium, and blow to mix the cell suspension evenly. Use a pipette to drop vertically on the well plate and shake it gently in an 8-shaped pattern. After the cells are evenly spread, they can be placed in a 37°C constant temperature cell culture incubator for culture.

[0141] 6. Cell freezing: Prepare cell freezing solution for immediate use, with a volume ratio of FBS:DMSO = 9:1. After absorbing all the old culture medium, wash with PBS for 1 minute, add 2mL 0.25% Trypsin-EDTA for digestion for 3 minutes, stop digestion after observing the morphology, discard the supernatant after centrifugation, add the corresponding volume of cell freezing solution according to the cell density to resuspend the cells, add the cell suspension to the cryopreservation tube, each tube has a volume of 1mL, mark the type and date, and put it into a gradient freezing box for gradient cooling: 4℃ cooling for 30min, -20℃ cooling for 2h, and finally store at -80℃. For long-term storage, it can be placed in liquid nitrogen.

[0142] 2.1.1 Cytotoxicity evaluation (CCK-8)

[0143] CCK8 stands for Cell Counting Kit-8 reagent, which can be used for simple and accurate cell proliferation and toxicity analysis. Its basic principle is: the reagent contains water-soluble tetrazolium salt WST-8 [chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonic acid benzene)-2H-tetrazolium monosodium salt], which is reduced to a highly water-soluble yellow formazan product (Formazan dye) by dehydrogenase in cells under the action of electron carrier 1-methoxy-5-methylphenazinium dimethyl sulfate (1-Methoxy PMS). The amount of formazan generated is proportional to the number of living cells. Therefore, this characteristic can be used to directly judge the cell proliferation results through cell viability to complete the toxicity analysis of the materials used in this study (F-PVs@M, F-PVs, PVs@M, PVs).

[0144] The specific experimental methods are as follows:

[0145] Cell seeding plate: In this study, 100 μL of cell suspension was added to a 96-well cell culture plate for HCECs toxicity experiment. The cell density was set to 5000 cells / well, and 100 μL of PBS was added to the wells around the plate to prevent evaporation from the edge of the wells. The plate was placed in a cell culture incubator and cultured at a constant temperature for 12 hours to allow HCECs to fully adhere to the wall. The cell status and density were observed under a microscope. If everything was normal, the next step could be performed.

[0146] Material incubation: First, use the culture medium to dilute the material concentration gradient. F-PVs@M, F-PVs, PVs@M, and PVs are set to 6 concentrations, namely 0, 40, 80, 160, 320, and 640 μg / mL. Take out the 96-well plate, remove the old culture medium, wash it 3 times with sterile PBS buffer, and then add 100 μL of cell culture medium containing the above polymer vesicle concentration or drug-loaded polymer vesicle concentration. Set five replicate wells for each concentration, and leave a blank well next to it with pre-added working solution as a blank control. Finally, place it in a cell culture incubator and culture it at a constant temperature for 24 hours.

[0147] Addition of CCK-8 solution: First, dilute the CCK-8 solution with complete cell culture medium at a ratio of 1:9 in a dark environment to prepare CCK-8 working solution for subsequent use. Gently aspirate the old culture medium containing nanoparticles in the 96-well plate, wash with sterile PBS buffer 3 times, 1 min each time, and finally add 100 μL CCK-8 working solution to each well, taking care not to generate bubbles. Throughout the experiment, the wells with 100 μL CCK-8 working solution but no cells were added were used as blank controls.

[0148] Calculation of cell viability: After continuing to incubate in a 37°C cell incubator in the dark for 1.0 h, use a microplate reader to measure the absorbance at 450 nm, remove the maximum and minimum values ​​of the five values ​​of the duplicate wells, calculate the average value of the blank group and the 0 concentration, and then calculate the cell viability of each well using the formula. The cell viability of each group is expressed as a percentage of the average value, and the standard deviation of each group is calculated using a T-test.

[0149] 2.1.2 Live and dead cell staining

[0150] Cell live / dead staining can be used to visually determine the ratio of live and dead cells, thereby exploring the biocompatibility of the material. This study used the Calcein / PI Cell Viability and Cytotoxicity Detection Kit (Calcein / PI CellViability), and the specific experimental procedures are as follows:

[0151] Seed plate: Seed plate is the same as 2.3.1.1, with three replicate wells in each group. Material incubation: Concentration setting and method are the same as 2.3.1.1.

[0152] Probe loading: discard the old culture medium containing nanoparticles in the 96-well plate, wash with PBS three times, 1 min each time, add the prepared staining working solution in a light-proof environment, 100 μL per well, and continue incubating in a 37°C cell constant temperature incubator in the dark for 30 min.

[0153] Observation and photography: After incubation in the dark for 30 min, the cells were observed and photographed using an inverted fluorescence microscope (DMi8) in a red light darkroom at a magnification of 10×.

[0154] 2.2 In vivo biocompatibility

[0155] In order to evaluate the biocompatibility of nanoparticles and whether the cornea and conjunctiva of normal mice would be damaged during treatment, we selected healthy wild-type C57BL / 6j mice as experimental subjects. All animal experiments were approved by the Animal Care and Utilization Ethics Committee of Wenzhou Medical University. These mice were provided by Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., all of which were wild-type C57BL / 6j female mice, weighing approximately 18-22 grams. They were raised in a standard breeding environment for 2 weeks to adapt to the new experimental environment. The following are the specific experimental steps:

[0156] Animal screening: Slit lamp photography was used to screen mice with healthy ocular surfaces: We used sodium fluorescein solution under cobalt blue light to observe whether there were defects in the mouse corneal epithelium. The sodium fluorescein solution would show bright green fluorescence at the defect site, which could accurately detect the integrity of the corneal epithelium and record it by taking photos at the same time.

[0157] Group experiment: 16 mice with healthy ocular surfaces were randomly divided into 4 groups, and F-PVs@M, PVs@M, F-PVs, and PVs eye drops at a concentration of 400 μg / mL prepared with sterile PBS were dripped into each group. The experimental period was 7 days, three times a day, 10 μL each time, 5 μL for each eye.

[0158] Evaluation: During the treatment, the intraocular pressure and weight of the mice were monitored regularly. The specific method of measuring intraocular pressure is as follows: gently open the upper and lower eyelids of the mouse to fully expose the surface of the eyeball, vertically align the tonometer to the center of the mouse cornea, touch the probe with appropriate force, and measure more than three times to take the average. After the seven-day eye drop, add fluorescein sodium solution to the eye surface and use the cobalt blue light of the slit lamp to evaluate again and take pictures and record.

[0159] Sacrifice and sampling: After the evaluation, the mice were sacrificed by cervical dislocation, and the eyeballs of the mice with eyelids were removed under a microscope using sterile corneal scissors. The advantage of this method is that the complete conjunctiva can be removed. The eyeballs were fixed in a freshly prepared fixative for 24 hours for subsequent tissue section evaluation.

[0160] Treatment of eyeball tissue: Remove the fixed eyeball and use a sterile surgical blade to cut off the posterior pole under a microscope to squeeze out the lens. The purpose is to balance the pressure inside and outside the eye and avoid deformation of the eyeball during dehydration. Place it in physiological saline to remove residual fixative.

[0161] Paraffin embedding: Place the processed eyeball tissue in a marked embedding box, use an automatic dehydrator to perform alcohol gradient dehydration overnight, and place it in high-temperature paraffin the next day to fully penetrate the wax before embedding. When embedding, first spread a shallow layer of paraffin on the bottom, then place the tissue in and adjust it to the appropriate position: the coronal and sagittal planes should be perpendicular to the bottom of the embedding box at the same time. After slightly cooling and fixing, fill it with paraffin and place it on a cold table to cool. If the position of the eyeball changes, it can be reheated and melted for a second embedding.

[0162] Paraffin sections: Place the embedded paraffin-embedded samples on a paraffin slicer for continuous sectioning with a thickness of 5 μm. Select the sections of the central pupil area and adhere them to the adhesive slides. Place them in a 60°C oven for 2 hours for preliminary dewaxing so that the protein tissue can firmly adhere to the slides.

[0163] Slice staining and photography: After taking it out of the oven, put it into the set automatic staining machine for H&E hematoxylin-eosin staining. After the end, put it in the fume hood for more than 30 minutes, and then use neutral resin to seal the slide. The completed tissue slide needs to be placed in the fume hood for more than 48 hours to dry before it can be photographed. Check whether it has overflowed glue, shifted, or broken coverslips. After removing it, use a 3D slide scanner to scan and photograph it.

[0164] 3. Study on the biocompatibility of polymer vesicles

[0165] Although the pathogenesis of DED has not yet been fully elucidated, oxidative damage and the subsequent inflammatory response have been considered to be the key to the vicious cycle of dry eye disease, and clearing ROS is the key to dry eye treatment.

[0166] Due to the presence of boron ester groups, all obtained nano / macro objects have the ability to decompose in response to external triggers (especially H2O2). The introduction of polymer vesicles can further enhance their stimuli-responsiveness. This responsiveness and degradability can enable polymer vesicles to release drugs through passive diffusion and active triggering processes, responding to the environment while also achieving the effect of scavenging ROS.

[0167] 3.1 Evaluation of ROS responsiveness of F-PVs

[0168] In order to verify whether F-PVs are ROS-responsive, 200 μM H2O2 was added to a 0.2% w / w F-PVs solution. TEM images were taken at specific time points: 10 min, 30 min, and 1 h to observe the changes in the morphology of the polymer vesicles.

[0169] 3.2 Evaluation of the ROS scavenging ability of F-PVs in vitro

[0170] We used 200μM H2O2 to stimulate a cell model that simulated oxidative damage. In order to visualize and quantitatively study intracellular ROS, CM-H2DCFDA was used as a fluorescent probe, and the groups were set up as follows: the group stimulated with H2O2 but not incubated with drugs was the control group, and the group without any treatment was the blank group.

[0171] Seed plate: Prepare HCECs cell suspension (same steps as 2.3.1.1), and the cells are plated at 5×10 3 The cells were uniformly seeded in a 96-well plate at a density of 100 / mL and placed in a 37°C constant temperature cell culture incubator for 24 hours to allow the cells to adhere to the wall and grow.

[0172] Adding drugs: After confirming that the cells have grown on the wall, set up experimental group, control group and blank group respectively. Add 200 μM F-PVs empty vesicles to the experimental group and continue culturing for 24 hours.

[0173] Probe loading: cells were loaded with 10 μM CM-H2DCFDA in the dark for 30 min.

[0174] H2O2 stimulation: After adding the prepared 200μM H2O2 to the corresponding groups, the well plate was placed in a constant temperature incubator away from light to stimulate HCECs for 2h. Observation and photography: Photography was performed using an inverted fluorescence microscope (DMi8, Leica) with an objective lens magnification of 20×.

[0175] IV. Fluoridation Effect Assessment

[0176] In order to evaluate the ability of fluorinated vesicles to improve the ability to penetrate the physiological barrier of the cornea and cell membrane, this study explored multiple levels through cells, in vitro tissues and in vivo. Since FITC fluorescence has high sensitivity and long luminescence lifetime, and can detect fluorescent signals at low concentrations, FITC was used to label polymer vesicles, and F-PVs@FITC and its control group PVs@FITC were prepared for cell uptake, corneal diffusion evaluation, and ocular surface penetration experiments.

[0177] 4.1 Cellular uptake

[0178] Cell uptake experiment is an experimental technique used to study the absorption and transport mechanism of substances in cells. This study adopts this method to study and analyze the cell uptake of fluorescently labeled polymer vesicles. By comparing the difference in uptake at different time points, it is verified whether the fluorinated vesicles have a fluorination effect of rapid penetration compared with the fluorinated vesicles. The specific steps are as follows.

[0179] Cell seeding and sample addition: Seed the cells according to the method in 2.3.1.1. Add 5 μL of PBS to a sterile 24-well plate to facilitate cell adsorption. The number of cells seeded per well is 5×10 4 After adding the cell suspension, shake the well plate slightly in an 8-shaped pattern to evenly spread it, and then place it in a 37°C cell culture incubator for constant temperature culture for 24 hours. First, observe the cell state under a microscope. After it is completely attached to the wall, the drug addition operation can be performed. After discarding the old culture medium, wash it three times with PBS, add 300μg / mL of F-PVs@FITC and PVs@FITC at different time points, and make the final co-incubation time 0.5, 2, 4 and 6h. Set two replicate wells at each time point, and protect from light throughout the process.

[0180] Nuclear staining: After discarding the old culture medium containing nanoparticles in the wells in a light-proof environment, wash with PBS three times, and add 500μL of cell fixative to each well to fix the cells for 30 minutes. Then aspirate the fixative in the wells and wash with PBS three times, 1 minute each time. Drop the anti-fluorescence quenching sealing solution containing DAPI on the adhered slide, and buckle the removed cell slide on the slide. After standing for 10 minutes, seal with nail polish and store in a refrigerator at 4°C.

[0181] Confocal microscope photography: Use a confocal microscope 880 to select the corresponding channel for photography in a light-proof environment, with an objective lens magnification of 63×.

[0182] 4.2 Corneal penetration diffusion assessment

[0183] To further explore the fluorination effect of F-PVs, this study used ex vivo corneal tissue for penetration diffusion evaluation.

[0184] Four experimental rabbits were randomly divided into two groups, a fluoride group and a control group, and euthanized. According to the "Guidelines for Euthanasia of Laboratory Animals", 2% sodium pentobarbital and sulphuric acid were intravenously injected into the experimental rabbits. After they were deeply anesthetized, they were killed by air embolism and their eyeballs were quickly removed. Then, the fresh cornea was dissected and separated and placed between the donor chamber and the receptor chamber of the Franz diffusion cell. Equal amounts of F-PVs@FITC and PVs@FITC were added to the donor chamber, and sufficient receptor solution (such as 1% fluoride) was added to the receptor chamber. Figure 6 ). 0.4 mL of receptor solution was collected at different time points, and 0.4 mL of fresh receptor solution was added. Subsequently, the fluorescence signal was detected using an automatic fluorescence microplate reader to determine and calculate the concentration of FITC-labeled F-PVs that penetrated the cornea. The cumulative permeability calculation formula is: Cumulative permeability = [Rn×V1+(Rn-1+Rn-2+Rn-3...+R1)×V2]×100% / Rall×V3, where Rn is the fluorescence value of the receptor solution collected for the nth time, Rn-1 is the fluorescence value of the receptor solution collected for the nth time, R1 is the fluorescence value of the receptor solution collected for the first time, Rall is the fluorescence value of the sample in the donor cavity, V1 is the volume of the total receptor solution, V2 is the volume of the collected solution, and V3 is the volume of the sample solution in the donor cavity.

[0185] 4.3 Ocular surface penetration

[0186] In order to verify the penetration effect of F-PVs in vivo, the distribution of F-PVs@FITC and PVs@FIT C eye drops in the mouse cornea and conjunctiva at different time points was detected. This experiment used wild-type C57BL / 6j female mice provided by Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., weighing approximately 18-22 grams. They were raised in a standard breeding environment for 2 weeks to adapt to the new experimental environment. The following are the specific experimental steps:

[0187] Screening and grouping: Eight mice with healthy ocular surfaces with no corneal damage or edema and negligible green after fluorescein sodium staining were randomly divided into two groups: experimental (fluoridation) group and control (non-fluoride) group. Eye drops: In a light-proof environment, F-PVs@FITC and PVs@FITC loaded with FITC fluorescent probes were used to continuously drop eyes on mice, 5 μL per eye, 5 minutes apart each time, for a total of 10 drops.

[0188] Sacrifice and sampling: The animals were killed by dislocation of the neck immediately after the end of the experiment, and the eyeball tissue with eyelids removed was placed in 4% paraformaldehyde for fixation.

[0189] Frozen embedding: After 6 hours of sucrose dehydration, observe whether the tissue is dehydrated, then embed, drop OCT glue into the embedding frame, and pay attention to expel bubbles. Before placing the eyeball, wash the residual sucrose solution with OCT glue, and adjust the position of the eyeball: make sure that the coronal and sagittal planes of the eyeball are perpendicular to the bottom of the embedding frame at the same time. If there are bubbles, they can be expelled. Finally, use liquid nitrogen to quickly freeze and store in a -80℃ refrigerator overnight, then transfer to a -20℃ refrigerator for storage.

[0190] Sectioning and staining: The next day, frozen sections were made with a thickness of 10 μm. After about 20 minutes, when the sections returned to room temperature, PBS was added to the surface of the samples for washing, 5 minutes each time, for a total of 3 times. Then, 100 μL of anti-fluorescence quenching agent containing DAPI was used to seal the sections.

[0191] Observation and photography: Two-photon confocal fluorescence microscopy was used to observe and photograph tissue local areas, with an objective lens of 10×.

[0192] 5. Evaluation of the efficacy of polymer vesicles in treating dry eye

[0193] In order to evaluate the in vivo clinical therapeutic effect of fluorinated drug-loaded vesicles F-PVs@M on dry eye, the animal selection was the same as 2.2. The following are the specific experimental steps:

[0194] 5.1 SCOP-DED mouse model

[0195] After the mice were placed in the environment for one week to adapt, the mice with no damage to the ocular surface were selected by slit lamp observation for unified modeling. The modeling method was as follows: 2.5 mg / mL of scopolamine was injected subcutaneously three times a day (9:00 am, 14:00 p m, 19:00 pm) and kept in an intelligent environmental control system (wind speed 2.1 ± 0.2 m / s, relative humidity 30 ± 5%, temperature 21-23 ° C). During the experiment, food, water and animal behavior were not restricted. The light in the breeding environment was irradiated from the ceiling above to the bottom, with an illumination of 18 lux and a 12 / 12h day / night cycle. Some healthy mice were left as the NC group, without modeling, and sodium hyaluronate eye drops were used daily to maintain tear film stability. After one week of modeling, in order to maintain the stability of the model, subcutaneous injections of 2.5 mg / mL scopolamine were continued three times a day during the second week of treatment.

[0196] 5.2 Grouping and treatment

[0197] On the seventh day of modeling, the mouse eyes were stained with sodium fluorescein and observed and recorded by slit lamp. A total of 36 mice with successful modeling and 6 mice with healthy ocular surface and no disease were selected as the Normal group. In order to verify whether the fluoridation effect can make the nano drug-loaded particles have outstanding therapeutic effects in the clinical treatment of dry eye, and the therapeutic effect after loading the MCC950 drug that specifically inhibits NLRP3, the modeling mice were randomly divided into 6 groups: F-PVs@M, PVs@M, F-PVs, PVs, MCC950, SCOP. The total treatment time was one week, with eye drops three times a day (9:00am, 14:00pm, 19:00pm), 5μL in each eye, of which the SCOP group used sterile PBS eye drops, and the Normal group continued to use sodium hyaluronate eye drops.

[0198] 5.3 Evaluation

[0199] Slit lamp observation: Corneal barrier function and integrity are evaluated using corneal sodium fluorescein staining, which is an important evaluation indicator of the severity of dry eye.

[0200] On the 1st, 3rd, 5th and 7th days of treatment, a slit lamp was used to observe the fluorescein sodium staining and take photos. The specific method was as follows: 2 μL of fluorescein sodium (2 mg / mL) was dripped into the conjunctival sac, assisted blinking 2-3 times, and photographed under cobalt blue light 2 minutes later. Finally, two professional ophthalmologists performed dry eye scoring. The scoring criteria were as follows: First, the cornea was divided into five areas: left, right, top, bottom and center. Each quadrant was scored according to the following criteria: no staining was 0 points; superficial punctate staining was 1 point; diffuse staining was 2 points; and fluorescein plaques were 3 points. Finally, the scores of the left, right, top, bottom and center areas were summarized as the final score.

[0201] Tear secretion content: Tear secretion is one of the important indicators of lacrimal gland function in ophthalmological clinical examinations. We measured it at 0 and 7 days as a before and after comparison. Cut it into 1-2 cm lengths, clamp it with sharp forceps, fold one end into a right angle, and insert it into the outer canthus of the mouse's lower eyelid. Fix the mouse for 20 seconds and then take it out to measure the length.

[0202] Intraocular pressure measurement: Determine whether the intraocular pressure is at a normal value on days 0, 1, 3, 5, and 7 of treatment. Weight measurement: Determine whether the body weight is at a normal value on days 0, 1, 3, 5, and 7 of treatment. Corneal and conjunctival H&E staining: After 7 days of treatment, the mice were killed by cervical dislocation, and the sampling method, paraffin section and H&E staining method were the same as 2.3.2. Conjunctival goblet cell count: The mucin layer is mainly produced by conjunctival goblet cells, and the number of goblet cells is also one of the important indicators for diagnosing the severity of dry eyes. The longitudinal section of the mouse eyeball was globally scanned by a 3D slide scanner, and the conjunctival part was cut to count the goblet cells, and 3 slides were counted in each group. The results are expressed as mean ± standard deviation.

[0203] VI. Evaluation of anti-inflammatory and antioxidant effects in vitro

[0204] 6.1 Sampling

[0205] 1. Cell seeding plate: Use mouse macrophage RAW264.7 cells that have grown to more than 80% in a culture flask to prepare a cell suspension. The method is the same as (the steps are the same as 2.3.1.1). Dilute the cell suspension to a concentration of 7×10 4 / mL was added to a 24-well plate, and the groups were set up as: F-PVs experimental group, PVs control group, positive control group, negative control group, 1mL per well, and placed in a 37℃ cell constant temperature incubator for culture overnight.

[0206] 2. Stimulation: The next day, discard the spent culture medium and add 320 μg / mL of empty vesicle F-PVs and PVs for incubation. After 24 hours, add lipopolysaccharide (LPS) to the first three groups to a final concentration of 1 μg / mL. Continue to culture in the cell culture incubator for 24 hours.

[0207] 3. Take the supernatant: transfer the cell culture medium (about 900 μL per well) to a sterile centrifuge tube, centrifuge at 12,000 rpm for 10 min at 4°C, then divide the supernatant into small EP tubes and store them in a -80°C refrigerator for subsequent experiments.

[0208] 6.2 Enzyme-linked immunosorbent assay (ELISA)

[0209] 4. 30 minutes before the experiment, remove the samples to be tested and the standards, sample diluent, concentrated enzyme conjugate, biotinylated antibody, washing solution, colorimetric substrate and other reagents and return them to room temperature.

[0210] 5. Prepare the cleaning solution: dilute the 20× concentrate into 1× application solution using deionized water.

[0211] 6. Gradient dilution of standard: dilute the standard concentration into different gradients (IL-6 is 500, 250, 125, 62.5, 31.25, 15.63, 7.81 pg / mL; IL-1β is 2000, 1000, 500, 250, 125, 62.5, 31.25 pg / mL; TNF-α is 2000, 1000, 500, 250, 125, 62.5, 31.25 pg / mL).

[0212] 7. Biotin antibody working solution: dilute 100× antibody concentrate into 1× application working solution.

[0213] 8. Enzyme conjugate working solution: dilute 100× antibody concentrated enzyme conjugate into 1× application working solution and prepare it for use immediately.

[0214] 9. Washing: Add 300 μL of 1× washing solution to each well of the ELISA plate, soak for 30 seconds, quickly shake off the liquid in the plate, and pat the plate dry on filter paper.

[0215] 10. Sample addition: Add 100 μL of 2-fold diluted standard to each well of the standard sample well, and add 100 μL of the sample to be tested to the sample well.

[0216] 11. Incubation: Seal the plate with a sealing template and incubate in a 37°C incubator for 90 min.

[0217] 12. Washing: Wash four times, using the same method as step 6.

[0218] 13. Add antibody: Add 100 μL of biotin antibody working solution into the reaction well.

[0219] 14. Incubation: Seal the plate with a sealing template and incubate in a 37°C incubator for 60 min.

[0220] 15. Washing: Same as 9.

[0221] 16. Add enzyme conjugate: Add 100 μL of enzyme conjugate to the reaction well.

[0222] 17. Incubation: Seal the plate with a sealing template and incubate in a 37°C incubator for 30 min.

[0223] 18. Washing: Wash five times, using the same method as step 6.

[0224] 19. Color development: Add 100 μL of the color development substrate TMB to each well and develop the color at 37°C in the dark for 15 min.

[0225] 20. Stop: Add 15 μL of stop solution to each well. The order of adding samples is the same as 12.

[0226] 21. Measurement and calculation: Use an enzyme-labeled instrument to quickly measure the OD value of each well at 450nm absorbance. Use Excel polynomials to draw a standard curve with the concentration of the standard as the horizontal axis and the absorbance OD value as the horizontal axis to calculate the content of inflammatory factors in the sample.

[0227] 7. Study on dry eye pathway mechanism-tissue immunofluorescence

[0228] Immunofluorescence (IF) is a powerful technique based on immunology, biochemistry and microscopy. The main principle is to use fluorescently labeled antibodies as probes to locate and qualitatively analyze specific antigens in tissues or cells. In order to verify the therapeutic effects of PBS, MCC950, PVs, F-PVs, PVs@M, and F-PVs@M on dry eye, dual-color immunofluorescence staining was used to detect the expression of inflammatory factors (NLRP3, Casepase-1, IL-6, and IL-1β) in dry eye model tissues. The specific steps of dual-color tissue immunofluorescence staining are as follows.

[0229] Sampling: Under a microscope, use corneal scissors to remove the entire mouse eyeball with eyelids and place it in fixative for 24 hours. Use a surgical blade to cut the posterior pole to squeeze out the crystal, and dehydrate with a freshly prepared 30% sucrose solution overnight. The next day, embedding was performed, and OCT glue was dripped into the embedding frame. Be careful to discharge bubbles. Before placing the eyeball in the embedding frame, wash away the residual sucrose solution in the OCT glue, and adjust the position in the embedding frame: after the coronal and sagittal planes of the eyeball are perpendicular to the bottom of the embedding frame at the same time, if there are bubbles, they can be picked out, and after quick freezing with liquid nitrogen, placed in a -80℃ refrigerator for storage overnight, it can be transferred to -20℃ for storage. Before slicing, the embedded tissue and blade need to be placed in the slicer in advance for precooling for 10 minutes, and then sliced ​​at a thickness of 5μm, directly attached using an adhesive slide, and stored in a -20℃ refrigerator for tissue immunofluorescence staining.

[0230] Primary antibody incubation: After the ice slices stored at -20℃ are restored to room temperature, wash the slices with PBS 3 times, 5 minutes each time. After washing, use an immunohistochemistry pen to draw circles around the corneal and conjunctival tissues, and then use 4% paraformaldehyde to fix the tissues for 15 minutes. Wash the slices with PBS 3 times, 5 minutes each time, and then use blocking solution to block at room temperature for 1 hour. Add the diluted primary antibody to the tissue, place it in a wet box and shake it in a 4℃ refrigerator overnight. After the primary antibody is recovered the next day, wash the slices with PBS 3 times, 5 minutes each time.

[0231] Secondary antibody incubation: Use the diluted dual-color fluorescent secondary antibody diluent to drop on the tissue, incubate at room temperature for 2 hours, and protect from light throughout the process. Wash the tissue 3 times with PBS, each time for 5 minutes.

[0232] Staining, sealing and photography: After staining with DAPI for 3 minutes, wash with PBS three times, 5 minutes each time, and finally seal the slides with an anti-fluorescence quencher that does not contain DAPI. Store at 4°C in the dark and photograph using a confocal microscope with an objective lens magnification of 20x.

[0233] 8. Experimental Results

[0234] 8.1 Successful preparation of polymersomes

[0235] 8.1.1 Structural Analysis of Diblock Copolymers

[0236] 8.1.1.1 Synthesis and characterization of macromolecular chain transfer agents

[0237] Firstly, the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA was synthesized by reversible addition-fragmentation chain transfer polymerization (RAFT) method. 1 HNMR) was used to characterize the synthesis of P(PEGMA9-co-TFEMA3)-CTA. The test solvent was Chloroform-d. The results are shown in Figure 7 As shown. 1 In the H NMR spectrum (A), proton signals generated from -CH2 of TFEMA (4.2-4.3 ppm), -CH2 of PEGMA (4.0-4.5 ppm), and -CH2 of the benzene ring of the entire polymer (7.0-8.1 ppm) were clearly observed.

[0238] The same method was used to synthesize the control macromolecular chain transfer agent PPEGMA9-CTA. 1 In the H NMR spectrum (B), proton signals generated from -CH2 of PEGMA (4.0-4.5 ppm) and -CH of the benzene ring of the entire polymer (7.0-8.1 ppm) were clearly observed.

[0239] 8.1.1.2 Synthesis and Characterization of Diblock Polymers

[0240] The fluorinated diblock polymer P(PEGMA9-co-TFEMA3)-b-PPTBA50 and the control group fluorinated diblock polymer PPEGMA9-b-PPTBA50 were synthesized by polymerization-induced self-assembly. The synthesis was characterized by 1H NMR, and the test solvent was Chloroform-d. The results are shown in Figure 8 As shown. In the 1H NMR spectrum in (A), the proton signals generated by -CH2 of PTBA (4.8-5.1ppm), -CH2 of PEGMA (4.0-4.5ppm), the methylene of TFEMA (4.1-4.3ppm), and -CH of the benzene ring of the entire polymer (7.0-8.5ppm) were clearly observed. In the 1H NMR spectrum in (B), the proton signals generated by -CH2 of PTBA (4.8-5.1ppm), -CH2 of PEGMA (4.0-4.5ppm), and -CH of the benzene ring of the entire polymer (7.0-8.5ppm) were clearly observed.

[0241] 8.1.2 Particle size and morphology of polymer vesicles

[0242] 8.1.2.1 Particle size of polymersomes

[0243] The particle sizes of six nanoparticles, F-PVs, F-PVs@M, PVs, PVs@M, F-PVs@FITC, and PVs@FITC, and their stability in water were studied by DLS. Fig. 9 shown. Fig. 9 (A) is the particle size distribution diagram of F-PVs and F-PVs@M. The results show that the average particle size of the empty nanoparticles F-PVs is 155.6nm, and the dispersion index (PDI) is 0.07, indicating that the F-PVs are uniformly distributed. The average particle size of the drug-loaded nanoparticles F-PVs@M is 202.6nm, and the PDI is 0.08, indicating that the distribution of F-PVs@M is also very uniform. Fig. 9 (B) is the particle size distribution diagram of PVs and PVs@M. The results show that the average particle size of the empty nanoparticles PVs is 131.1nm, and the dispersion index (PDI) is 0.1293, indicating that the distribution of PVs is uniform. The average particle size of the drug-loaded nanoparticles PVs@M is 153.9nm, and the PDI is 0.19, indicating that the distribution of PVs@M is also very uniform. And the average particle sizes of F-PVs@FITC and PVs@FITC in (CD) are 159.9nm and 193.1nm, respectively, and the PDIs are 0.29 and 0.22, respectively.

[0244] 8.1.2.2 Morphology and elemental analysis of polymersomes

[0245] The surface morphology and distribution of four nanoparticles, F-PVs, F-PVs@M, PVs, and PVs@M, were observed by TEM. Fig.10 As shown: F-PVs and F-PVs@M nanoparticles are spherical structures, and different light and dark phenomena appear, which shows that F-PVs are not solid spheres but hollow spheres with a size of 173.9nm, which is a vesicle-like structure.

[0246] like Fig.11 PVs and PVs@M nanoparticles. It can be clearly seen that they are the same as F-PVs and F-PV s@M. They are all spherical structures and have different brightness and darkness. This shows that PVs is the same as F-PVs, a vesicle-like structure with a size of 138nm.

[0247] Since F-PVs contain fluorine (F) and PVs do not contain F, EDS-mapping elemental analysis can be performed using TEM. Fig.12 As shown, the dark field image of F-PVs on the left and the F element (mint blue) image on the right, it can be clearly seen that the shell of each white vesicle is covered with F elements, while PVs ( Fig.13 ) does not exist; blue dots appear in the background of both images, which is due to the inevitable noise during the shooting process, and Fig.12 The color and density of the blue dots in the middle vesicle shell are stronger than the background, indicating the presence of F element in F-PVs and the absence of F element in the control group.

[0248] 8.1.3 Packet Loading Rate

[0249] FS was used as a simulated drug for MCC950 to test the encapsulation efficiency. The free FS was calculated according to the standard curve, and the encapsulation efficiency of F-PVs@M was 24.3%, and the encapsulation efficiency of PVs@M was 21.5%.

[0250] 8.1.4 In vitro release monitoring

[0251] The hydrophobic groups in the PTBA fragment can be oxidized into hydrophilic groups, which can increase the pores of the polymer vesicles F-PVs and help accelerate the release of the drugs loaded in the inner cavity to the outside world. Because the solubility and molecular weight of FS are similar to those of MCC950, and FS can be simply measured by an ELISA instrument for its fluorescence intensity, and has excellent spectral properties, extremely low FS concentrations can also be detected, so the use of FS is helpful for the detection of release behavior.

[0252] In this study, the in vitro release behavior of FS was investigated by using vesicles loaded with sodium fluorescein (F-PVs@FS). The experiment was divided into three groups: 0mM H2O2, 10mM H2O2, and 100mM H2O2. Fig.14 As shown in the figure, at 1h, the cumulative release rates of 0mM H2O2, 10mM H2O2 and 100mM H2O2 were 10.0%, 37.4% and 49.9%, respectively. In the presence of H2O2, the release of FS showed a rapid release trend from the beginning. More obviously, at the 2nd hour, the cumulative release rates were 12.0%, 51.6% and 70.0%, respectively. This result further shows that with the increase of time, under the condition of 100mM H2O2, the cumulative release rate increased by 20.1% compared with that of 1h, followed by 10mM H2O2, and 0mM H2O2 was the slowest, with an increase of only 2%. At the 10th hour, the release reached equilibrium, which was 12.7%, 56.9% and 86.9%, respectively. It can be seen that under the condition of high low concentration H2O2, the FS release rate has reached more than 85%. The above results show that the release of loaded drugs can be accelerated when active oxygen, such as H2O2, is present.

[0253] 8.2 Biocompatibility evaluation of drug-loaded polymer vesicles

[0254] 8.2.1 In vitro biocompatibility assessment

[0255] Different concentrations of F-PVs@M, F-PVs, PVs@M, and PVs were co-incubated with cells for 24 hours, and the biocompatibility of polymer vesicles before and after drug loading was quantitatively analyzed using CCK-8 and cell live-dead staining qualitative experiments.

[0256] 8.2.1.1 Cytotoxicity (CCK-8 test)

[0257] The cytotoxicity of F-PVs, PVs, F-PVs@M, and PVs@M on HCECs was investigated by CCK-8 method, and the cell viability was detected after 24 h of co-incubation. Fig.15 As shown in the figure, the concentration was set to six different gradients of 0-640μg / mL, and the cell viability was above 85%, and the cell viability was the highest at 160μg / mL. The viability of F-PVs@M and PVs@M was slightly lower than that of F-PVs and PVs, which may be due to the encapsulation of MCC950. In summary, the cell viability detected by CCK-8 shows that F-PVs, PVs, F-PVs@M, and PVs@M all have good biocompatibility.

[0258] 8.2.1.2 Live and dead cell staining

[0259] Calcein AM was used to stain live cells, which showed green fluorescence; propidium iodide (PI) was used to stain dead cells, which showed red fluorescence. Then the corresponding channel of DMi8 was used to shoot. The shooting results are shown in the figure below. Fig.16 As shown, it can be intuitively found that compared with the blank group 0 μg / mL, the cell morphology of the high concentration 640 μg / mL group underwent some changes, but the number of dead cells was less, while the pseudopodia of cells in the 320, 160, 80, and 40 μg / mL groups were obvious, and the number of dead cells was negligible, which corresponded to the CCK-8 results, indicating that the prepared drug-loaded polymer vesicles had good biocompatibility.

[0260] 8.2.2 In vivo biocompatibility assessment

[0261] 8.2.2.1 Slit lamp evaluation

[0262] First, mice with healthy ocular surface and no corneal and conjunctival edema were screened under slit lamp, and the slit lamp was used to photograph them before dripping the medicine. Three times a day, 400 μg / mL F-PVs@M, PVs@M, F-PVs, and PVs eye drops were dripped into the left and right eyes 5 μL each, and the ocular surface condition was recorded again with slit lamp after one week. Fig.17 The before and after comparison shown in the figure shows that the mouse eye surface is smooth, there is no corneal edema and neovascularization, and there is no inflammation of the cornea and conjunctiva. It appears clear blue under cobalt blue light, and the green fluorescence is negligible.

[0263] 8.2.2.2 Histopathological sections

[0264] On the seventh day after eyedrop, the mice were euthanized, and the intact eyeball tissue was removed with the eyelids embedded in paraffin. The cut paraffin sections were stained with H&E. The tissue sections were photographed as shown in the figure: Fig.18 It was observed that the cornea and conjunctiva of the F-PVs@M, PVs@M, F-PVs and PVs groups had clear and complete layers, tightly arranged cells, and a structurally complete stratified columnar epithelial structure in the fornix. There was no infiltration of inflammatory factors, and there were no significant differences in quantity and morphology.

[0265] The iris contains melanin, blood vessels, and smooth muscle, and is mainly composed of connective tissue, located between the cornea and the lens. The retina is the inner layer of the eyeball wall, and there is no detachment. The overlapping layers of cells are clearly visible. The retinal pigment epithelium and the ciliary body are closely connected, and it can be observed that the ciliary body section forms a complete triangle.

[0266] 8.2.2.3 Intraocular pressure and body weight

[0267] After 7 days of monitoring, there were no abnormalities in the intraocular pressure and body weight of the mice. Fig.19 , all fluctuated within the normal range.

[0268] In summary, F-PVs@M, PVs@M, F-PVs, and PVs did not cause eye inflammation in mice, and the mice remained in a healthy state overall. This was consistent with the results of in vitro biocompatibility experiments, indicating that F-PVs@M, PVs@M, F-PVs, and PVs all had good biocompatibility.

[0269] 8.3 Fluorinated polymer vesicles improve uptake and ocular surface penetration

[0270] Since fluorinated polymers have the ability to quickly penetrate physiological and cell membrane barriers, it is estimated that the cellular uptake and ocular surface penetration ability of fluorinated vesicles F-PVs are greatly improved compared with non-fluorinated vesicles PVs.

[0271] 8.3.1 Assessment of cellular uptake

[0272] Cellular uptake is the use of fluorescent dyes or isotopes to track and observe the process of cells taking up external substances. In this study, FITC-labeled polymer vesicles F-PVs@FITC, PVs@FITC and HCECs were co-incubated at a concentration of 40 μg / mL for 0.5, 2, 4, and 6 hours, and then photographed using a confocal microscope.

[0273] exist Fig. 20It can be clearly observed that at 0.5h, there was obvious fluorescence aggregation around the cells in the fluorinated F-PVs group. At 2h, a part of F-PVs@FITC had entered the cells. As time went on, the trend of cell uptake was very significant. At 6h, the F-PVs@FITC blocks overlapped with the cell nucleus. Although there was fluorescence aggregation in the non-fluorinated PVs group, the number was less than that of F-PVs at the same time point, indicating that F-PVs were more easily taken up by cells than PVs, thanks to the ability of fluorinated polymer vesicles to quickly penetrate the cell membrane.

[0274] 8.3.2 Corneal penetration diffusion assessment

[0275] The penetration of F-PVs and PVs into the cornea was evaluated using the Franz diffusion cell method with isolated rabbit corneas. In this experiment, different F-PVs@FITC and PVs@FITC were added to the donor cavity, and the penetration of F-PVs and PVs into the recipient cavity was measured based on the fluorescence signals at different time points. Fig.21 As shown, fluorinated vesicles F-PVs have enhanced penetration ability compared with PVs.

[0276] 8.3.3 Ocular surface penetration assessment

[0277] 100 μg / mL F-PVs@FITC and PVs@FITC were continuously dripped into the eyes of mice, and the uptake of F-PVs@FITC and PVs@FITC by the cornea and conjunctiva was evaluated by the fluorescence distribution. Fig. 22 and 23 As shown, it can be observed that the fluorescence of the PVs group is mainly retained in the surface layer of the cornea and conjunctiva, with only a small part being absorbed, while most of the F-PVs group is evenly distributed in the corneal and conjunctival tissues.

[0278] 8.4 ROS responsiveness and ROS scavenging effect of fluorinated polymer vesicles

[0279] 8.4.1 Responsiveness of fluorinated polymersomes

[0280] In order to explore whether F-PVs are ROS-responsive and achieve the effect of rapid drug release under oxidative stress, we used low-concentration H2O2 to simulate the ROS environment and observed the morphological changes of the vesicles at 10min, 30min, 60min and without H2O2. Fig.24 From the TEM images, we can see that the vesicles triggered disassembly process was very fast; after adding H2O2 for 10 min, the ordered internal structure of the vesicles became broken and chaotic, and was almost completely decomposed after 60 min. This indicates that the decomposition of the vesicles was caused by the degradation of PTBA in response to external triggers (H2O2).

[0281] 8.4.2 ROS scavenging effect of fluorinated polymer vesicles

[0282] Excessive ROS can directly or indirectly lead to corneal epithelial dysfunction. In order to explore the ability of fluorinated polymer vesicles to scavenge ROS, HCECs were stimulated with H2O2 to simulate cellular oxidative damage in dry eyes. Fig.25 Compared with the blank group, the number and intensity of fluorescence in the model group increased significantly, indicating that the level of intracellular ROS increased significantly. When HCECs were co-incubated with 200 μg / mL F-PVs fluorinated polymer vesicles, the ROS content was significantly reduced as determined by fluorescence, indicating that F-PVs has a good ability to scavenge ROS.

[0283] 8.5 Evaluation of the efficacy of polymersomes in the treatment of SCOP-DED

[0284] 8.5.1 In vivo evaluation of polymersomes in the treatment of SCOP-DED mice

[0285] 8.5.1.1 Slit lamp observation and sodium fluorescein staining scoring

[0286] According to the research needs, the therapeutic effects of drug-loaded vesicles, empty vesicles and free drugs were evaluated in scopolamine (SCOP)-induced dry eye mice. Eye drops were applied three times a day, and slit lamp examinations were performed on days 0, 1, 3, 5, and 7. The sodium fluorescein staining scores were evaluated after recording under cobalt blue light. It is expected that the fluorinated drug-loaded vesicles F-PVs@M have the best therapeutic effect, followed by the non-fluorinated drug-loaded vesicles PVs@M, and the empty fluorinated vesicles F-PVs have better therapeutic effects than the empty non-fluorinated vesicles PVs. Representative images 26 and 27 verified the above viewpoints: on the 7th day of modeling, the modeling groups all had patchy and large diffuse flake green staining, with scores ranging from 14 to 15 points, indicating that the modeling was successful. The corneal epithelium of the NC group, which was not treated with scopolamine, was smooth and flat, showing a clean blue outline, with no obvious pigment attachment, and scores ranging from 0 to 1 point.

[0287] As the treatment time went by, the treatment groups all produced therapeutic effects to varying degrees. The fluorinated vesicles have the function of quickly penetrating barriers such as the cornea and cell membranes. The therapeutic effect of F-PVs@M is significantly better than that of PVs@M, and the staining scores are also statistically significant: P = 0.0004 < 0.001. The treatment began to improve on the first day, and a more prominent therapeutic effect appeared on the third day. On the fifth day, the mouse scores fluctuated between 3-4, and had recovered to a critical state of health. On the seventh day, it was no different from the NC group, and statistical analysis was performed: P = 0.0003 < 0.001; and compared with PVs, F-PVs had a better therapeutic effect, with a statistical difference: P = 0.029 < 0.01. However, since PVs@M is loaded with the NLRP3 blocking drug MCC950, the therapeutic effect is better than that of F-PVs, and statistical analysis also verifies this: P = 0.0001 < 0.001. Since PTBA has the function of scavenging ROS, the therapeutic effects of PVs and free MCC950 were similar, and there was no significant difference in statistical analysis: P = 0.063 > 0.05.

[0288] 8.5.1.2 Tear secretion

[0289] Tear secretion experiment is one of the key evaluation indicators for diagnosing dry eye. The tear secretion of B6 mice was measured using Schirmer test I. Fig.28 As shown, the average tear secretion volume of the NC group remained around 4.57mm, and the average tear secretion volume of the modeling group (SCOP and treatment group) was between 1.2mm-1.3mm. After 7 days of treatment, the average value of the free drug MCC950 group increased from 1.26mm to 2.06mm, and the average value of the PVs group increased from 1.29mm to 2.19mm, with no significant statistical difference compared with the MCC950 group: P value was 0.4900>0.05. The mean value of the F-PVs group increased from 1.27mm to 2.95mm, which was significantly different from the PVs group: P value was 0.0031<0.01, the mean value of the PVs@M group increased from 1.22mm to 3.6mm, and the mean value of the fluorinated drug-loaded vesicles F-PVs@M group increased from 1.26mm to 4.52mm, which had no significant statistical difference compared with the NC group: P value was 0.6566>0.05, and had significant statistical difference compared with PVs@M: P value was 0.0029<0.01. The above results show that: 1. F-PVs@M can restore tear secretion to normal; 2. The recovery effect of fluorinated vesicles is significantly better than that of fluoride-free vesicles.

[0290] 8.5.1.3 Intraocular pressure and body weight

[0291] The intraocular pressure and body weight of mice were monitored at 0, 1, 3, 5, and 7 days to explore whether they were in a normal state. Fig.29As shown in the figure, the intraocular pressure of SCOP modeling fluctuated within the normal range. Since subcutaneous injection of scopolamine had a slight effect on the eating state of mice, the body weight of mice after modeling was slightly lower than the average value of the normal group, but after 7 days of treatment, the F-PVs@M group had returned to normal values. The other groups also recovered to varying degrees.

[0292] 8.5.2 Analysis of corneal, conjunctival and retinal pathology

[0293] 8.5.2.1 Analysis of conjunctival goblet cell numbers

[0294] Goblet cells on the conjunctiva secrete mucin to maintain the stability of the tear film. The number of goblet cells can be used to evaluate the treatment of dry eyes. Fig.30 The results of histopathological sections show that the number of goblet cells in the SCOP group decreased sharply compared with the NC group, with a significant statistical difference: P<0.0001. After 7 days of treatment, the number of goblet cells in the F-PVs@M group has returned to normal. After statistical analysis with the NC group, it was found that P=0.5839>0.5, with no significant difference. The recovery of the number of goblet cells in other groups was the same as the trend of sodium fluorescein score and tear secretion content. The analysis results are as follows: There are significant differences between the NC group and the PVs@M, F-PVs, PVs, and MCC950 groups, P<0.0001; there is no significant difference between the PVs group and the MCC950 group, P=0.6809>0.5.

[0295] 8.5.2.2 Cornea and retina

[0296] like Fig.31 The corneal epithelial cells of the SCOP model are arranged in a disorderly manner and irregular in shape, inflammatory cells are scattered, and the corneal epithelial morphology is also missing, which is irregular compared with the NC group. In the F-PVs@M group, it can be observed that the corneal epithelial cells are neatly arranged and have a normal cubic structure. The retinal pigment epithelium and the neuroepithelium are closely connected, no retinal detachment is observed, and the cells of each layer are clearly visible. The SCOP model and eye drops will not cause damage to the fundus, which once again verifies that F-PVs@M has good biocompatibility.

[0297] 8.6 Anti-inflammatory effects of polymersomes in vitro

[0298] A nonspecific in vitro inflammatory model was constructed by inducing RAW264.7 macrophages with LPS. After co-incubation with F-PVs and PVs, the supernatant was taken and the expression of downstream inflammatory factors of the inflammatory cascade, interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α), was detected by ELISA kit. The results are shown in Fig.32As shown in the figure, the expressions of related inflammatory factors were significantly increased after LPS stimulation, and the expressions of various inflammatory factors decreased to varying degrees after PVs and F-PVs treatment, among which the effect of F-PVs was more significant.

[0299] 8.7 Polymer vesicles regulate NLRP3-Casepase-1-IL-1β signaling pathway to treat dry eye

[0300] To elucidate the mechanism of action of F-PVs@M in the treatment of DED, 5 μm frozen sections of SCOP-DED mouse eyeball tissue were used for tissue immunofluorescence staining to monitor the expression of NLRP3, Casepase-1, IL6, and IL-1β in the cornea and conjunctiva, and to verify the anti-inflammatory effects of F-PVs@M and other treatment groups. Fig.33 and 34 As shown in the figure, F-PVs@M, PVs@M, F-PVs, PVs, and MCC950 can inhibit the expression of NLRP3, Casepase-1, IL-6, and IL-1β in corneal and conjunctival tissues compared with the SCOP group. Among them, the F-PVs@M group has the strongest inhibitory effect, which is the same as the NC group. This shows that after F-PVs@M treatment, the inflammation in the dry eye model is reduced and has returned to the level of normal mice. The ability of other groups to reduce inflammatory factors has the same trend as the previous clinical treatment effect. Among them, because MCC950 has a specific effect of inhibiting NLRP3, it is slightly different from the trend of clinical treatment effect. The fluorescence intensity of the MCC950 group is weaker than that of the PVs group, which is similar to that of F-PVs. The anti-inflammatory effects of F-PVs@M and F-PVs are stronger than those of PVs@M and PVs, which once again verifies that the F-PVs@M group has a better therapeutic effect due to the fluorination effect. In summary, by loading F-PVs@M with the NLRP3 inhibitor MCC950, the inflammatory response is reduced by targeting the ROS-NLRP3-Casepase-1-IL-1β signaling axis, achieving the effect of effectively treating dry eyes.

[0301] In the present invention, a macromolecular chain transfer agent and a diblock polymer are firstly synthesized by the RAFT method. 1The methylene groups of PEGMA (4.0-4.2ppm) and TFEMA (4.1-4.3ppm) and -CH2 of PTBA (4.8-5.1ppm) were clearly observed in H NMR, indicating the successful synthesis of the polymer. Then, polymer empty vesicles F-PVs and PVs and drug-loaded vesicles F-PVs@M and PVs@M were prepared by solvent conversion method. The results of TEM showed that the morphology of F-PVs, PVs, F-PVs@M and PVs@M were all vesicle-like. The results of DLS showed that their particle sizes were 155.6nm, 202.6nm, 131.1nm and 153.9nm, respectively, which was consistent with the TEM results. The PDI was lower than 0.2, indicating good dispersibility. The entrapment rates of FS in F-PVs and PVs were calculated to be 24.3% and 21.5%, respectively. In the in vitro release monitoring experiment, the drug release was accelerated in the presence of 100mMH2O2, indicating that ROS accelerated the drug release.

[0302] The results of in vitro cell experiments showed that F-PVs, PVs, F-PVs@M, and PVs@M were non-toxic to human corneal epithelial cells even at a high concentration of 640 μg / mL, and the in vivo biocompatibility results in animals also showed that F-PVs, PVs, F-PVs@M, and PVs@M did not damage animal corneal conjunctiva and corneal epithelial cells, indicating that the polymer vesicles have good biocompatibility.

[0303] In order to observe cell uptake, the in vitro endocytosis behavior of F-PVs was evaluated by confocal microscopy. The results showed that as time went on, the number of green fluorescent particles (FITC@F-PVs) around the cell nucleus increased, indicating that F-PVs could be well taken up, which would be helpful for subsequent research. In addition, penetration diffusion experiments of isolated rabbit corneas and further in vivo ocular surface penetration experiments showed that F-PVs had a good fluorination effect and could quickly penetrate the anatomical barrier of the ocular surface.

[0304] By observing the TEM images at different time points, it was verified that in a low concentration of H2O2 environment, F-PVs had good ROS responsiveness and could quickly release drugs, which was consistent with the previous in vitro release monitoring results; further, through the removal of intracellular reactive oxygen species, it was proved that F-PVs had the ability to remove intracellular H2O2, indicating that it has antioxidant capacity.

[0305] Further in vivo dry eye treatment experiments were conducted using the SCOP-DED animal model. The slit lamp score and tear secretion content verified that F-PVs@M had the best therapeutic effect, while other groups also showed a step-by-step therapeutic effect. The weight of the mice decreased after modeling, and returned to normal after treatment, which indirectly verified the good therapeutic and safety of F-PVs@M. The results of H&E staining of paraffin sections showed that the number of goblet cells in the experimental group had returned to normal, and the slit lamp scores of other groups were consistent, showing a step-by-step increase.

[0306] The results of tissue immunofluorescence showed that F-PVs, PVs, PVs@M, MCC950, and SCOP all had clear fluorescence signals, but the fluorescence signal of the F-PVs@M group was almost invisible, indicating that compared with the control groups: F-PVs, PVs, PVs@M, MCC950, and SCOP, the F-PVs@M group had a better effect in inhibiting the secretion of inflammatory factors (NLRP3-Casepase-1-IL-1β, IL-6). Elisa results also proved that F-PVs has a good ability to inhibit inflammatory factors IL-6, IL-1β, and TNF-α. In summary, the F-PVs@M group has an excellent effect in the synergistic treatment of dry eye by clearing excess ROS in the ocular surface microenvironment and inhibiting NLRP3 inflammasomes.

[0307] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A ROS-responsive fluorinated polymer vesicle, characterized in that: It is prepared by first dissolving a fluorinated diblock polymer in a good solvent, then dissolving it in an aqueous phase and fully hydrating it; The fluorinated diblock polymer is poly(ethylene glycol) methyl ether methacrylate-trifluoroethyl methacrylate-phenyl borate, and the fluorinated polymer vesicle is a vesicle-like structure with a hollow interior and an average particle size of 140-170 nm.

2. The ROS-responsive fluorinated polymer vesicle according to claim 1, characterized in that The good solvent is DMF, and the usage ratio of the fluorinated diblock polymer to the good solvent is (9-11) mg:1 mL.

3. The ROS-responsive fluorinated polymer vesicle according to claim 2, characterized in that The fluorinated diblock polymer is dissolved in a good solvent to form a solution A, and the volume ratio of the solution A to the aqueous phase is 1:(1.8-2.2).

4. A method for preparing ROS-responsive fluorinated polymer vesicles as claimed in any one of claims 1 to 3, characterized in that: The steps include: S1. Synthesis of macromolecular chain transfer agent: Using DMF as solvent, chain transfer agent CTA, AIBN as free radical initiator, PEGMA and TFEMA through reversible addition-fragmentation chain transfer polymerization to prepare the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA; S2. Synthesis of phenylboronic acid ester: 4-(Hydroxymethyl)phenylboronic acid pinacol ester was dissolved in excess anhydrous DCM, excess TEA was added, and after cooling, acryloyl chloride was added thereto to obtain phenylboronic acid ester through reaction; S3. Synthesis of fluorinated diblock polymers: The fluorinated diblock polymer was prepared by reversible addition-fragmentation chain transfer polymerization of phenyl borate with photoinitiator LAP as free radical initiator and macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA as chain transfer agent. S4. Synthesis of fluorinated polymer vesicles: The fluorinated diblock polymer is first dissolved in a good solvent, then dissolved in an aqueous phase and fully hydrated to obtain fluorinated polymer vesicles.

5. The method for preparing ROS-responsive fluorinated polymer vesicles according to claim 4, characterized in that: In the step S1, the chain transfer agents CTA, AIBN, PEGMA and TFEMA are in a molar ratio of 1: (0.18-0.22): (8-10): (2.7-3.3).

6. The method for preparing ROS-responsive fluorinated polymer vesicles according to claim 4, characterized in that: In the step S2, the molar ratio of 4-(hydroxymethyl)phenylboronic acid pinacol ester to acryloyl chloride is (9-11):

1.

7. The method for preparing ROS-responsive fluorinated polymer vesicles according to claim 4, characterized in that: In the step S3, the photoinitiator LAP, the macromolecular chain transfer agent P(PEGMA9-co-TFEMA3)-CTA, and the phenyl borate ester are in a molar ratio of 1:(1.8-2.2):(89.9-109.9).

8. The method for preparing ROS-responsive fluorinated polymer vesicles according to claim 4, characterized in that: In the step S4, the good solvent is DMF, the usage ratio of the fluorinated diblock polymer to the good solvent is (9-11) mg:1 mL, the fluorinated diblock polymer is dissolved in the good solvent to form solution A, and the volume ratio of solution A to deionized water in the aqueous phase is 1:(1.8-2.2).

9. A pharmaceutical composition, characterized in that The fluorinated polymer vesicles according to any one of claims 1 to 3 are used as carriers to in situ encapsulate MCC950.

10. Use of the pharmaceutical composition according to claim 9, characterized in that: The pharmaceutical composition is used for preparing a pharmaceutical preparation for treating dry eye.